Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer pulls sickle cell treatment Oxbryta
Pfizer withdraws sickle-cell disease treatment
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
Pfizer’s Strategy Looks Shakier After Sickle-Cell Disappointment
The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.
Pfizer Sickle Cell Drug Suspended by Europe in New Setback
All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement Wednesday. The company, which also announced discontinuing clinical trials as it investigates the findings,
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) shares declined Thursday after the drug maker recalled all lots of its sickle cell disease medicine worldwide because of concerns it could lead to severe pain and possibly death in patients.
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and “fatal events.”
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left scrambling to figure out what to do.
Medscape
7h
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
7h
Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
‘Ring of fire’ eclipse in Oct
Illegal cloning sentencing
NYC tunnel shutdown
Grammy-winning singer dies
Trump's Erie rally
Blocks songs from artists
Crew-9 astronauts at ISS
Harris' Las Vegas rally
Oil prices climb
Actor John Ashton dies
Firefighters injured in crash
Three PFLP leaders killed
Defensive Player of the Year
Sells stake in DirecTV
Line Fire prompts evacuation
Israeli forces launch raids
US wins Presidents Cup
Newsom vetoes AI safety bill
$567M Taiwan defense aid
37 militants killed in Syria
‘Wild Robot' tops box office
NC small plane crash
Temporary outage fixed
'Days of Our Lives' star dies
Ga. chemical plant fire
Condemns Israeli strikes
Ukrainian drones shot down
Steward CEO to step down
Faces fine to end Brazil ban
Chief adviser subpoenaed
Feedback